tradingkey.logo

Quantum BioPharma Ltd

QNTM
查看詳細走勢圖
8.890USD
+0.070+0.79%
收盤 12/19, 16:00美東報價延遲15分鐘
33.93M總市值
虧損本益比TTM

Quantum BioPharma Ltd

8.890
+0.070+0.79%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.79%

5天

-5.22%

1月

+43.62%

6月

-74.60%

今年開始到現在

+141.58%

1年

+196.33%

查看詳細走勢圖

TradingKey Quantum BioPharma Ltd股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Quantum BioPharma Ltd當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名166/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價40.25。中期看,股價處於下降通道。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Quantum BioPharma Ltd評分

相關信息

行業排名
166 / 404
全市場排名
296 / 4582
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 2 分析師
買入
評級
40.250
目標均價
+297.33%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Quantum BioPharma Ltd亮點

亮點風險
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
估值合理
公司最新PE估值-1.00,處於3年歷史合理位
機構加倉
最新機構持股1.17M股,環比增加17.86%

Quantum BioPharma Ltd新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Quantum BioPharma Ltd簡介

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
公司代碼QNTM
公司Quantum BioPharma Ltd
CEOKotra (Lakshmi P)
網址https://www.quantumbiopharma.com/

常見問題

Quantum BioPharma Ltd(QNTM)的當前股價是多少?

Quantum BioPharma Ltd(QNTM)的當前股價是 8.890。

Quantum BioPharma Ltd 的股票代碼是什麼?

Quantum BioPharma Ltd的股票代碼是QNTM。

Quantum BioPharma Ltd股票的52週最高點是多少?

Quantum BioPharma Ltd股票的52週最高點是52.000。

Quantum BioPharma Ltd股票的52週最低點是多少?

Quantum BioPharma Ltd股票的52週最低點是3.900。

Quantum BioPharma Ltd的市值是多少?

Quantum BioPharma Ltd的市值是33.93M。

Quantum BioPharma Ltd的淨利潤是多少?

Quantum BioPharma Ltd的淨利潤為-14.20M。

現在Quantum BioPharma Ltd(QNTM)的股票是買入、持有還是賣出?

根據分析師評級,Quantum BioPharma Ltd(QNTM)的總體評級為買入,目標價格為40.250。

Quantum BioPharma Ltd(QNTM)股票的每股收益(EPS TTM)是多少

Quantum BioPharma Ltd(QNTM)股票的每股收益(EPS TTM)是-8.891。
KeyAI